MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 84 filers reported holding MERSANA THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $119,267 | -6.1% | 16,704 | +0.2% | 0.00% | – |
Q3 2022 | $127,000 | +47.7% | 16,669 | -0.4% | 0.00% | – |
Q2 2022 | $86,000 | -98.2% | 16,737 | -98.6% | 0.00% | -100.0% |
Q1 2022 | $4,665,000 | +427.1% | 1,157,635 | +2004.4% | 0.00% | +100.0% |
Q1 2021 | $885,000 | +486.1% | 55,011 | +567.4% | 0.00% | – |
Q4 2020 | $151,000 | +228.3% | 8,243 | +233.6% | 0.00% | – |
Q3 2020 | $46,000 | -97.8% | 2,471 | -97.4% | 0.00% | -100.0% |
Q2 2020 | $2,116,000 | +8038.5% | 93,663 | +1953.6% | 0.00% | – |
Q4 2019 | $26,000 | +420.0% | 4,561 | +43.5% | 0.00% | – |
Q3 2019 | $5,000 | -58.3% | 3,179 | +5.3% | 0.00% | – |
Q2 2019 | $12,000 | +1100.0% | 3,019 | +1605.6% | 0.00% | – |
Q4 2018 | $1,000 | 0.0% | 177 | +103.4% | 0.00% | – |
Q3 2018 | $1,000 | -80.0% | 87 | -69.3% | 0.00% | – |
Q2 2018 | $5,000 | +66.7% | 283 | +45.1% | 0.00% | – |
Q1 2018 | $3,000 | – | 195 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 1,191,271 | $6,980,848 | 6.79% |
Bain Capital Life Sciences Investors, LLC | 8,663,673 | $50,769 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 950,000 | $5,567,000 | 3.43% |
Sarissa Capital Management LP | 3,997,010 | $23,422,479 | 2.79% |
Decheng Capital Management III (Cayman), LLC | 904,268 | $5,299,010 | 1.98% |
SILVERARC CAPITAL MANAGEMENT, LLC | 1,140,182 | $6,681,467 | 1.91% |
Orbimed Advisors | 9,011,437 | $52,807,021 | 1.01% |
Opaleye Management Inc. | 460,000 | $2,695,600 | 0.94% |
Artal Group S.A. | 2,200,000 | $12,892 | 0.72% |
DAFNA Capital Management LLC | 413,463 | $2,422,893 | 0.68% |